Latest Immunotherapy Treatments

Gavo-Cel Moving to Phase II Trial for Mesothelioma

A study looking at T-cell therapy for mesothelioma is going to phase II of the clinical trial process. Researchers are trying to find out how effective the treatment is when combined with an approved immunotherapy combination. Researchers are looking at the relationship between gavocabtagene autoleucel (gavo-cel) with the combination of[…]

Read More »

Enzyme and Chemotherapy Combination for Mesothelioma

Pleural mesothelioma sufferers could improve their survival by as much as 30 percent when treated with the latest cancer enzyme and chemotherapy. In a recent study known as ATOMIC Meso, ADI-PEG 20 showed effectiveness when used for sarcomatoid and biphasic mesothelioma, the two most resistive to treatment. The enzyme is[…]

Read More »

STAR-101 Could Make CAR T-Cell Therapy More Effective for Mesothelioma Patients

Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the University of Pennsylvania. The Food and Drug Administration gave orphan drug status to SynKIR-110, a CAR T-cell therapy utilized for[…]

Read More »

Allocetra and Cisplatin Combination for Mesothelioma

A new immunotherapy treatment is showing promising results against mesothelioma. The therapy consists of a combination of two drugs: one drug that reprograms macrophages and the other is the chemotherapy cisplatin. Mesothelioma is a cancer that does not respond well to treatment. The best option for patients is a combination[…]

Read More »

Drug Factories Treatment Being Tested for Mesothelioma

Researchers have found a treatment that can eradicate advanced stage mesothelioma tumors within a few days. The research is being done at Rice University and Baylor College of Medicine. The treatment utilizes implants known as “drug factories” and a checkpoint inhibitor drug. Mesothelioma is a tough to treat cancer of[…]

Read More »

Keytruda as a Second Line Treatment for Mesothelioma

A new second line treatment has been developed for pleural mesothelioma. The treatment was created at the Netherlands Cancer Institute in Amsterdam. Research was done as a single-arm, open-label clinical trial combining pembrolizumab (Keytruda) and lenvatinib. The results were presented at the IASCL 2022 World Conference on Lung Cancer in[…]

Read More »

SMARTEST Trial Hopes to Improve Survival Times for Mesothelioma

Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer Center in Toronto. The trial is known as SMARTEST, which stands for Surgery for Mesothelioma After Radiation Therapy using Exquisite[…]

Read More »

Galinpepimut-S Cancer Vaccine in Combination with Opdivo

Promising results from a study on pleural mesothelioma were recently released. The study found when patients were treated with a new combination treatment, patients lived longer and had a better quality of life. The phase I clinical trial utilized a targeted cancer vaccine known as galinpepimut-S (GPS) and the immunotherapy[…]

Read More »

Targeted Therapy is Showing Promising Results for Mesothelioma

Targeted research is advancing the treatment of pleural mesothelioma. Results from a study on a novel protein inhibitor known as tazemetostat (brand name Tazverik) were recently released. It is showing impressive results as a second line treatment for mesothelioma patients with the BAP1 genetic mutation. The control rate for disease[…]

Read More »

Vudalimab for the Treatment of Mesothelioma

The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]

Read More »